Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Year: 2018
Type: article
Institutions: The University of Sydney, Royal North Shore Hospital, UNSW Sydney, The George Institute for Global Health, University Medical Center Groningen, University of Groningen, Stanford Medicine, Stanford University, Janssen Research & Development (United States), University of Oxford, The George Institute for Global Health, Royal Prince Alfred Hospital, Imperial College London
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: canagliflozin, type 2 diabetes, renal outcomes, SGLT2 inhibitors, end-stage renal disease, renal failure, estimated glomerular filtration rate, albuminuria, albumin-creatinine ratio, serum creatinine doubling, cardiovascular risk, CANVAS trial, renal safety, cardiovascular events, dose escalation, HbA1c, atherosclerosis
Open Access status: green
OpenAlex ID: W2808915250
